Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy
1. BMY and JNJ halted Phase 3 Librexia ACS trial due to efficacy concerns. 2. No new safety issues were identified with milvexian in the trial. 3. Other Librexia trials for AF and SSP are recommended to continue. 4. BMY shares declined 3.59% following the trial termination announcement. 5. Previous trials, including Camzyos and Reblozyl, also failed to meet endpoints.